首页> 外文期刊>European journal of anaesthesiology >Assessment of the performance of the Marsh model in effect site mode for target controlled infusion of propofol during the maintenance phase of general anaesthesia in an unselected population of neurosurgical patients
【24h】

Assessment of the performance of the Marsh model in effect site mode for target controlled infusion of propofol during the maintenance phase of general anaesthesia in an unselected population of neurosurgical patients

机译:未选择的神经外科患者群体在全身麻醉维持阶段靶控丙泊酚输注靶控输注的作用部位模式下Marsh模型的性能评估

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND Propofol target-controlled infusion (TCI) in effect site mode has become popular since it became commercially available. OBJECTIVE We have performed a study to assess the pharmacokinetic performance of the Marsh model in effect site mode in an unselected group of patients during neurosurgery during the maintenance phase of anaesthesia. DESIGN Fifty American Society of Anesthesiologists (ASA) physical status classes 1 to 3 adults underwent elective neurosurgery receiving propofol TCI using the Marsh model in effect site mode. Propofol dose titration and level of patient monitoring was determined by the attending anaesthesiologist. Arterial blood was sampled at regular intervals during the maintenance phase of anaesthesia and measured plasma propofol concentrations were compared with those estimated using TCI. SETTING Large tertiary referral centre in Birmingham, UK, with a specialist neuroanaesthesia service. PATIENTS Fifty ASA status I to III adult patients undergoing elective neurosurgery. MAIN OUTCOME MEASURES Performance of Marsh model as assessed by median performance error (bias) and median absolute performance error (imprecision). RESULTS Performance of the Marsh model showed a positive bias (median performance error) of 27.6%, and imprecision (median absolute performance error) of 29.4%. Analysis of pooled data demonstrated greatest bias in the early phase (15 to 30 min) of anaesthesia (mean prediction error of 51.6%). Analysis of covariates demonstrated that obesity (BMI 30 kgm -2) contributed around half of the bias detected (mean prediction error 47 vs. 23%, P0.001). Patients with advanced age and significant comorbidity (ASA physical status class 2) actually demonstrated significantly lower prediction errors. CONCLUSION Pharmacokinetic analysis suggests that the performance of the Marsh model in effect site mode is poor in this broad patient population. The greatest bias demonstrated occurred in the early maintenance phase of anaesthesia. Of the covariates analysed, obesity contributed most significantly to an increased bias. Despite overall poor performance of the Marsh model, attending anaesthesiologists modified targeted propofol concentrations only 0.3 times per hour on average, using remifentanil dose modification nine times more frequently, with good surgical conditions in all patients.
机译:背景技术自有效部位模式下的异丙酚靶标控制输注(TCI)自从其市售以来已变得流行。目的我们进行了一项研究,以评估在麻醉维持阶段神经外科手术中未选出的一组患者中,Marsh模型在有效部位模式下的药代动力学性能。设计五十个美国麻醉医师学会(ASA)的身体状况等级为1至3的成年人接受了选择性的神经外科手术,接受了使用有效部位模式下的Marsh模型接受异丙酚TCI的治疗。异丙酚的剂量滴定和患者监测水平由主治麻醉医师确定。在麻醉维持阶段定期采样动脉血,并将测得的血浆丙泊酚浓度与使用TCI估算的浓度进行比较。设置英国伯明翰的大型三级转诊中心,提供专业的神经麻醉服务。患者接受择期神经外科手术的五十至ASA状态I至III成年患者。主要观察指标通过中位性能误差(偏差)和中位绝对性能误差(不精确度)评估的Marsh模型的性能。结果Marsh模型的性能显示正偏差(中位数性能误差)为27.6%,不精确度(中位数绝对性能误差)为29.4%。汇总数据分析显示,在麻醉的早期阶段(15至30分钟)存在最大偏差(平均预测误差为51.6%)。协变量分析表明,肥胖症(BMI> 30 kgm -2)占所检测偏倚的一半左右(平均预测误差47%vs. 23%,P <0.001)。年龄较大且合并症严重的患者(ASA身体状况等级> 2)实际上显示出较低的预测误差。结论药代动力学分析表明,在这种广泛的患者人群中,在有效部位模式下Marsh模型的性能较差。所表现出的最大偏差发生在麻醉的早期维持阶段。在所分析的协变量中,肥胖对偏倚增加的影响最大。尽管Marsh模型的总体性能不佳,但与会的麻醉师平均仅将每小时调整的异丙酚浓度调整为0.3倍,瑞芬太尼的剂量调整频率提高了9倍,并且所有患者的手术条件均良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号